About
Tempest Therapeutics
TPST.US
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd.
Profile
- Company Name
- Tempest Therapeutics, Inc.
- Market
- NasdaqCM
- Founded
- --
- Industry
- --
- Fiscal Year End
- December 31
- Website
- www.tempesttx.com